Quelling the COVID-19 Cytokine Storm in Hospitalized Patients: Current Thinking, Emerging Data

Quelling the COVID-19 Cytokine Storm in Hospitalized Patients: Current Thinking, Emerging Data is organized by Paradigm Medical Communications, LLC.

Release Date: December 17, 2021 
Expiration Date: December 17, 2022

Description:
The search for optimal COVID-19 treatment remains an urgent priority, especially in hospitalized patients who are at the highest risk for mortality and other negative outcomes. An appreciation of the “cytokine storm” in severe COVID-19 has illuminated a role for interleukin-6 (IL-6) inhibition using tocilizumab, an IL-6 receptor blocker, or Janus kinase (JAK) inhibition in certain patients. Continually emerging data, evolving guideline recommendations, and confusion about patient selection and the optimal timing of treatment initiation challenge hospital-based clinicians to keep pace and make appropriate, evidence-based care decisions. This webinar reviews current thinking on the role of recommended immunomodulatory therapies and agents in the late-phase investigation, including the pathophysiological processes they target, contextualization of clinical trial data discussed and illustrated in whiteboard animations, and with expert-led discussion to help clinicians make individualized COVID treatment decisions in the hospital.

Learning Objectives:
Upon completion of this activity, participants should be able to:
• Identify key characteristics of COVID-19 pathophysiology that are associated with more progressive and severe disease
• Summarize the efficacy and safety of treatments that are recommended to treat hospitalized patients with severe COVID-19
• Make immunomodulatory treatment decisions (eg, agent selection and timing of initiation) for hospitalized patients with severe COVID-19 based on clinical characteristics and current data